administered MDS at a daily dose of 1,800mg to 25 patients with diabetic retinopathy for periods ranging from 12 to 48 months (mean : 28 months) and achieved the following results: 1) During the administration period total choles terol, triglyceride and fibrinogen levels were all maintained at significantly lower levels. 2) Eye fundus findings showed an improvement in 38.9% no change in 47. 2% and a deterioration in 13.9% of the cases. 3) No side-effects or abnormalities in clinical findings were observed in any of the cases even though clinical tests of hepatic function, renal function, blood chemistry, and urinalysis were conducted. The above results demontsrate that MDS has a marked effect on diabetic retinopathy, especially in cases with moderate to severe symptoms during the non-proliferative stage.
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retinopathy ; dextran sulphate ; cholesterol ; triglyceride ; fibrinogen Diabetic retinopathy can be charaterized as an obstructive vascular disorder and during its progressive stages, a reduction in fibrinolysis and an increase in blood fibrinogen occur, which lead to a tendency for intravascular blood coagula tion.
In recent years, the view has generally prevailed that during the initial rapid stages of proliferative retinopathy, the pathological condition is quite similar to that in DIC, and anticoagulant therapy has therefore been seen as the most likely means of treating this disease with chemotherapy1). Dextran sulfate has been gaining attention as a heparinoid substance and not only does it normalize coagulation and fibrinolysis but it has also been found to normalize lipid metabolism and so is highly regarded as a drug with great promise in the treatment of diabetic retinopathy. Nonetheless, few reports have been published describing the results of long-term treatment with this drug. The authors con ducted a study of the therapeutic effects of this drug on diabetic retinopathy. A 389 
SUBJECTS AND METHODS

Subjects
As shown in Table 1 . time since onset of diabetes ranged from 3 to 25 years with a mean onset time of 10 years in the 25 patients selected as subjects of this study. There were 10 male and 15 female patients ranging in age from 29 to 80 years with a mean age of 57.5. A breakdown by therapy shown there were 3 patients undergoing only diet therapy, 19 patients taking oral hypoglycemic drugs and 3 patients on insulin. Control before drug administration and during the coarse was evaluated using both the fasting blood glucose value, the blood glucose 2 hr after a meal and the evaluation criteria of Mimura. Control was found to be excellent in 4 cases, good in 15 cases, fair in 1 case and poor in 5 cases. Before treatment, eye fundus findings were classified according to the modified Scott method as ranging from Ia to IIIb, as shown in Table 2 . Evaluation of eye fundus findings. In all patients the posterior polar region of both eyes was photographically recorded on color eye fundus photos (posislides). Two to six photos were taken at one time with an eye fundus camera.
Blood biochemistry tests. Blood glucose, urine tests and body weight were determined every 2 to 4 weeks during hospital visits. Total cholestrol, triglyceride and fibrinogen were determined as a rule every 3 months. As in other diabetic patients, hepatic function, renal function and hematopoietic function were tested every 6 months.
RESULTS
We continuously administered MDS for a period of 12 to 48 months to a total of 36 retinopathic eyes and, as shown in Therapeutic effect classified by severity Table 4 presents a comparison of therapeutic results classified according to severity. Although half of the cases at stage IIIa exhibited improvement, not a single case at stage la showed improvement and indeed two la cases showed deterioration. Four eyes representing a third of the cases at stage IIa showed improvement and no cases showed deterioration. Only one case at stage IIIb showed deterioration. Although there were only two lib cases, one exhibited improvement and one deterioration.
Therapeutic effect classified by eye fundus findings Table 5 shows the changes in the eye fundus lesions in the 14 improved eyes and the 5 deteriorated eyes. Findings included improvement of soft exudates in Therapeutic effect classified by chemical control As shown in Table 6 , of the 19 cases with good control (27 eyes) improvement was seen in 11 eyes (41%) and deterioration in 4 eyes (15%). In the cases with poor control (9 eyes), improvement was seen in 3 eyes (35%) and deterioration in 1 eye (10%). Thus no significant difference was observed between these two groups. Also, there was no significant difference in effectiveness between male and female patients, and no significant age difference was observed in the effecti veness of MDS. 
DISCUSSION
Diabetic retinopathy occurs with increasing frequency as the period since onset of diabetes increases, and it has been recognized as clinically necessary for Although diabetes is thought to develop due to an insufficiency of insulin activity, it is not clear by what mechanism insulin insuffi ciency promotes diabetic microvascular disorders, but during the initial stages of retinopathy, debilitation of the capillaries occurs and it is thought that, at the time of proliferative retinopathy, blood coagulation is accelarated4). In the case of diabetes, changes occurring during the initial stages in the retinal blood vessels include an increase in vascular permeability and subsequently an increase in aggregability due to thromboxane A2 wcich is thought to lead to thrombus formation.
It is, however, still unclear by what mechanism insulin insufficiency promotes vascular permeability. Clinically, during the course of diabetes, an increase in coagulability and platelet aggregation and a decrease in fibrinolysis are observed and these conditions become more severe as retinopathy progresses. Thus in the past, hemostyptics were used in the treatment of diabetic retinopathy but these drugs were found to be harmful rather than helpful.
It is thought, however, that vascular reinforcers such as adrenochromic and flavinoid prepara tions are effective in treating retinopathy5). If we consider this matter from the standpoint of the pathological physiology of retinopathy as described above, a drug with a pharmacological action promoting fibrinolysis and inhibiting platelet aggregation would be the rational drug for treating retinopathy. MDS is a heparinoid type drug and Brown7)., Cohen et al. ) studied MDS using the crossover method and found that MDS significantly reduced triglyceride, and tended to reduce total cholesterol, and to decrease the amount of fibrinogen. A significant stimulation of fibrinolysis was observed with the plasminogen free plate method (Eug.+SK) and also a tendency for MDS to stimulate fibrinolysis was observed both with the fibrin standard plate method (Eug.+ SK), and the plasminogen free plate method (Eug.). The reduction in triglyceride is considered to be due to a 800 mg had no effect on platelet adhesion or aggregation but that it acted signifi cantly to normalize cases showing excess platelet adhesion. Thus based on these results, MDS can be considered to be a drug that can be clinically applied to diabetic retinopathy. Koike administered MDS at a daily dose of 1,800 mg for a period of 6 months to 22 patients and based on eye fundus findings he reported that it produced improvement in 9 cases, deterioration in 1 case and evaluation was not possible in 3 cases. Kamei administered MDS at a daily dose of 900mg to 17 patients and 1,800mg to 21 patients for a period of 2 years. During this period, no aggravation or new outbreak of retinopathy occurred, and two cases improved from a rating of Scott III to Scott II. Mine16) administered MDS in daily doses ranging between 900 and 1,350mg to 7 patients with a rating of Scott Ha and above for 18 months. Since in these five cases, normal fibrinolysis was maintained and no progress in the retinopathic condition was observed, he conjectured that MDS exhibited an effect in cases where the amount of fibrinogen increased bringing about a reduction in fibrinolysis. Yamamoto17) evaluated the efficacy of MDS based on fundus findings and visual acuity in 15 patients to which he administered MDS at a daily dose of 900mg over a period of 6 months. He discontinued administration to cases that showed no response after 6 months but an effect was observed in 10 patients (administration for 6 to 8 months). Based on Wagener's classification, MDS proved to be effective in 7 out of 9 cases at stages I and II with slight symptoms and in 3 out of 6 cases at stages III and IV with severe symptoms. In the patients with slight symptoms an improvement in the retinopathy was observed and the efficacy rate was especially high in those patients with good chemical control. Ooka et al.18 ) also administered 6 capsules of MDS per day (1,800mg) to 15 patients over a period of 6 to 60 weeks and reported the following results. According to eye fundus findings, MDS was markedly effective in 6 cases, effective in 6 cases and no change was seen in 3 cases. In ten patients at Wagener's stage III, it was markedly effective in 4, effective 3 and ineffective in 3 cases. Three cases improved from Wagener III to II, and 1 case improved from Wagener IV to II. Since MDS administration is known to be effective in cases with serious symptoms, these improvements in eye fundus findings are presumed to be attributable to MDS. Above we have briefly recapi tulated various clinical trials describing the effect of MDS on diabetic retinopathy and MDS can thus be clinically evaluated as effective in the treatment of reti nopathy. In this study, we administered MDS over a long term and studied its effect on the eye fundus, lipids, and fibrinogen. In regard to eye fundus findings, we periodically took photos of the eye fundus and they were objectively evaluted by Dr. Fukuda. However, the evaluation of our results is a little difficult since we did not establish a placebo control group. In regard to lipids, total cholesterol and triglyceride levels were significantly lower during the entire trial period and the same effect was seen with fibrinogen. These results confirm the efficacy of MDS on the lipid metabolism and coagulation system. Kakamura et al. 19 ) have observed a tendency for HDL-cholesterol to increase during MDS administration. Since most of our cases ranged from subjects with moderate symptoms or above during the non-proliferative or pre-proliferative stage (III B) and our results show an improvement rate of 39% and a deterioration rate of only 14%, the efficacy of MDS can be considered as verified. After more than a year of treat ment, the improvement rate was 9 eyes (50%) and the deterioration rate was only 2 eyes (10%) in cases at stages Tub and IIIa. Thus our findings during this period support the therapeutic effectiveness of MDS and agree well with the results of Ooka et al.18) . In contrast to this, although the number of cases with slight symptoms at stage la is quite small, still no improvement was observed and some cases were seen to deteriorate, so MDS does not appear to act effectively during the initial stage of retinopathy, but begins to display its efficacy when vascular obstructive lesions have become evident. Its period of greatest efficacy seems to begin with the appearance of moderate symptoms, starting at the non-proliferative stage of retinopathy. However, Yamamoto and Ooka et al.'s) have observed that MDS acts effectively even in cases with slight symptoms, so it appears to be necessary to study the effect of MDS on a larger number of cases with slight symptoms in the future in order to resolve this issue. Since improvement based on individual findings showed a reduction or disappearance in soft exudates, minute hemorrhag ing and blot hemorrhaging, ability of this drug to improve vascular lesions and blood conditions during the period of vascular obstruction and thrombus forma tion is strongly suggested by these results. The disappearance of neovasculation is thought to be due to the same pathological principles. Since in some cases deterioration was observed, therapy with MDS has limitations. The improve ment in hard exudatds is thought to be related to MDS's effect on improving lipid metabolism. In this study, glucose control was not seen to produce any signifi cant effect on the course of the disease, indicating that improving factors unrelated to the control of diabetes intervened, giving further confirmation of the effectiveness of this drug. No difference in efficacy was observed between males and females and no age differences were observed, but since the number of elderly patients who showed improvement was relatively small, it seems likely that with increasing age, retinopathic lesions become irreversible. In any case, during long term administration, lipid metabolism in diabetic patients was observed to im prove, fibrinogen level declined and retinopathy improved in 39% of the cases without a single case showing any side-effect. It can therefore be said that the clinical utility of MDS was confirmed.
